# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology ther...
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2999138/summary.html
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(9.95) per share which beat the analyst consensus estimate of $...